Maria Filiponi

Dr. Maria Filiponi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2018 in BMC Urology
Verified
Journal Article
Open access
PDF file
ATHANASIOS ZACHARIOUATHANASIOS ZACHARIOU
ATHANASIOS ZACHARIOU
CHARALAMPOS MAMOULAKISCHARALAMPOS MAMOULAKIS
CHARALAMPOS MAMOULAKIS
MFMaria Filiponi
Maria Filiponi
Fotios DimitriadisFotios Dimitriadis
Fotios Dimitriadis
JGJ. Giannakis
J. Giannakis
NSN. Sofikitis
N. Sofikitis
Αim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function. Eighty five sexually active women suffering from overactive bladder were prospectively enrolled in this study. Females were divided into two groups. In Group A (control), 48 patients received no treatment and in Group B, 37 patients received mirabegron 50 mg/daily for 3 months. Patients were evaluated with FSFI-Gr at the beginning of the study and again after a period of 3 months. In Group B, there was a significant increase post-treatment compared to baseline (p < 0.001) in total FSFI (20.3 (3.8) to 26.6 (4.2)) and all domains (desire: 3.0 (1.2) to 4.8 (1.2)), arousal: 3.0 (0.8) to 4.8 (0.9), lubrication: 3.9 (1.1) to 4.8 (1.2), orgasm: 3.6 (0.8) to 4.8 (1.0), satisfaction: 3.2 (0.4) to 4.0 (0.8) and pain: 3.2 (0.8) to 4.4 (1.2)). In Group A, there were no statistically significant changes in pre- and post-observation values. This study is one of the few demonstrating that management of OAB with mirabegron improves female sexual function. TRN ISRCTN17199301 , 20/10/2017, retrospectively registered.

Verified
Journal Article
Open access
PDF file
AZAthanasios Zikopoulos
Athanasios Zikopoulos
PKPeriklis Katopodis
Periklis Katopodis
MFMaria Filiponi
Maria Filiponi
AZAthanasios Zachariou
Athanasios Zachariou
ASAthanasia Sesse
Athanasia Sesse
Ioannis GeorgiouIoannis Georgiou
Ioannis Georgiou
Assisted reproductive technologies (ART) and, in particular, intracytoplasmic sperm injection (ICSI) transformed the management of male infertility by making fertility possible in previously untreatable cases. However, the bypassing of natural selection mechanisms at fertilization is fraught with the danger of transmission of genetic and epigenetic abnormalities. Male infertility is now a multifactorial disorder with notable contributions from single-gene defects, chromosomal abnormalities, and Y-chromosome microdeletions. The recent advances in next-generation sequencing and sperm omics have identified mutations and copy-number variations in genes critical for spermatogenesis, flagellar structure, and endocrine regulation. Along with these findings, an increasing body of evidence suggests that ART procedures can lead to a disruption of epigenetic reprogramming during gametogenesis and early embryogenesis, resulting in imprinting disorders and altered patterns of gene expression in the offspring. This review synthesizes recent progress in the molecular underpinnings of genetic and epigenetic hazards of ART, with an emphasis on clinical significance for reproductive counselling and ethical considerations for future generations.

15 September 2025 in Systems Biology in Reproductive Medicine
Verified
Journal Article
Closed access
MFMaria Filiponi
Maria Filiponi
ATHANASIOS ZACHARIOUATHANASIOS ZACHARIOU
ATHANASIOS ZACHARIOU
Advancements in the management of male infertility, particularly azoospermia, have significantly improved with the evolution of testicular biopsy techniques. This review explores the clinical applications and outcomes of three primary methods: testicular sperm aspiration (TESA), testicular sperm extraction (TESE), and microdissection TESE (mTESE). TESA remains a practical, minimally invasive solution for obstructive azoospermia, offering high success rates. However, its limited effectiveness in non-obstructive azoospermia (NOA) highlights the need for more refined approaches. mTESE has emerged as the preferred method in NOA cases due to its microsurgical precision, higher sperm retrieval rates, and reduced damage to testicular tissue. Multiple factors influence the success of these procedures, including patient age, testicular volume, hormone levels, and underlying histopathology. The identification of reliable predictive biomarkers such as follicle-stimulating hormone (FSH), inhibin B, anti-Müllerian hormone (AMH), and TEX101 has enhanced patient selection and procedural planning. Additionally, imaging techniques and metabolite profiling are emerging as valuable non-invasive tools for predicting outcomes. The integration of AI and machine learning into clinical practice further supports individualized treatment strategies by improving predictive accuracy and intraoperative decision-making. Despite clinical success, ethical and psychosocial considerations remain central to the comprehensive care of affected individuals. Financial constraints and unequal access to specialized reproductive services also pose challenges. Future efforts should prioritize the development of validated predictive models, the expansion of biomarker research, and the implementation of standardized clinical protocols. A multidisciplinary, patient-centered approach will be essential in optimizing outcomes for men facing infertility due to azoospermia.

20 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AZAthanasios Zikopoulos
Athanasios Zikopoulos
PKPeriklis Katopodis
Periklis Katopodis
MFMaria Filiponi
Maria Filiponi
AZAthanasios Zachariou
Athanasios Zachariou
ASAthanasia Sesse
Athanasia Sesse
Ioannis GeorgiouIoannis Georgiou
Ioannis Georgiou
Assisted reproductive technologies (ART) and, in particular, intracytoplasmic sperm injection (ICSI) transformed the management of male infertility by making fertility possible in previously untreatable cases. However, the bypassing of natural selection mechanisms at fertilization is fraught with the danger of transmission of genetic and epigenetic abnormalities. Male infertility is now a multifactorial disorder with notable contributions from single-gene defects, chromosomal abnormalities, and Y-chromosome microdeletions. The recent advances in next-generation sequencing and sperm omics have identified mutations and copy-number variations in genes crit-ical for spermatogenesis, flagellar structure, and endocrine regulation. Along with these findings, an increasing body of evidence suggests that ART procedures can lead to a disruption of epigenetic reprogramming during gametogenesis and early embryo-genesis, resulting in imprinting disorders and altered patterns of gene expression in the offspring. This review synthesizes recent progress in the molecular underpinnings of genetic and epigenetic hazards of ART, with an emphasis on clinical significance for reproductive counselling and ethical considerations for future generations.

11 September 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
ATHANASIOS ZACHARIOUATHANASIOS ZACHARIOU
ATHANASIOS ZACHARIOU
GDGrigorios Daligkaros
Grigorios Daligkaros
MFMaria Filiponi
Maria Filiponi
Primary carcinoma of the seminal vesicle is an exceptionally rare genitourinary malignancy, with evidence limited largely to case reports and small retrospective series. Diagnosis requires exclusion of more common secondary involvement from prostate, bladder, or rectal carcinoma through integration of clinical findings, imaging, histomorphology, and immunohistochemistry. Patients typically present with nonspecific symptoms and often have locally advanced disease. Computed tomography identifies retrovesical masses, while magnetic resonance imaging provides superior local staging. Core biopsy may establish the diagnosis, although definitive classification may require resection. The typical immunophenotype is CK7-positive, often with CA-125 expression, and negative for PSA, PAP, and NKX3.1; however, no marker profile is invariable. A contemporary panel including GATA3, p63/p40, uroplakin markers, CK20, p53, CD44, CDX2, and SATB2 is important for excluding urothelial and intestinal primaries. Conventional papillary adenocarcinoma is the predominant histological type, with mucinous, clear cell, squamous, and neuroendocrine variants also reported. Non-carcinomatous primary seminal vesicle neoplasms, including germ-cell tumours, sarcomas, solitary fibrous tumour, and mixed epithelial and stromal tumour, form an important differential diagnosis. Complete surgical excision with negative margins is the treatment most consistently associated with prolonged survival in the reported cases and is generally regarded as the only potentially curative option, whereas radiotherapy, chemotherapy, and hormonal therapy are selectively used for advanced or recurrent disease. International registries and collaborative molecular studies are needed to improve diagnosis, treatment, and follow-up.

Verified
Journal Article
Open access
PDF file
ATHANASIOS ZACHARIOUATHANASIOS ZACHARIOU
ATHANASIOS ZACHARIOU
EMEfthalia Moustakli
Efthalia Moustakli
AZAthanasios Zikopoulos
Athanasios Zikopoulos
MFMaria Filiponi
Maria Filiponi
Anastasios PotirisAnastasios Potiris
Anastasios Potiris
SSSofoklis Stavros
Sofoklis Stavros
Approximately 7% of males globally suffer from male infertility, which is becoming more widely acknowledged as a clinical indicator of potential health hazards as well as a cause of reproductive failure. Among these, cancer has become a significant worry due to mounting evidence that spermatogenesis impairment is associated with increased risk of prostate, testicular, and other cancers. Male infertility may be an early clinical manifestation of systemic genomic instability due to shared biological pathways, such as Y-chromosome microdeletions (AZF regions), germline DNA repair defects, mutations in tumor suppressor genes (e.g., BRCA1/2, TP53), mismatch repair gene mutations (e.g., MLH1, MSH2), and dysregulated epigenetic profiles. This narrative review covers the most recent research on prognostic markers of cancer in infertile men. These include molecular biomarkers such as genetic, epigenetic, and proteomic signatures; endocrine and hormonal profiles; and clinical predictors such as azoospermia, severe oligozoospermia, and a history of cryptorchidism. The possibility of incorporating these indicators into risk stratification models for precision medicine and early cancer surveillance is highlighted. For this high-risk group, bridging the domains of andrology and oncology may allow for better counseling, earlier detection, and focused therapies.